Author:
Chapman Jeremy R.,Wigmore Stephen J.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference8 articles.
1. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial.;Vink;Clin Infect Dis,2020
2. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients.;Callaghan;Transplantation
3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.;Munro;Lancet,2021
4. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.;Massa;Ebiomedicine,2021
5. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series.;Alejo;Transplantation,2021